Terns Pharmaceuticals, Inc. (FRA:430)

Germany flag Germany · Delayed Price · Currency is EUR
31.20
-0.60 (-1.89%)
At close: Jan 16, 2026
472.48%
Market Cap3.17B +728.7%
Revenue (ttm)n/a
Net Income-80.49M
EPS-0.88
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume133
Average Volume73
Open31.60
Previous Close31.80
Day's Range31.20 - 32.60
52-Week Range1.70 - 39.80
Betan/a
RSI43.89
Earnings DateMar 23, 2026

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic ... [Read more]

Industry Pharmaceutical Preparations
Founded 2016
Employees 59
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 430
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements